Becton Dickinson to Sell Clontech in Q2 or Q3, Official Says; Buyer Remains Undisclosed | GenomeWeb

SAN FRANCISCO, Jan. 12 (GenomeWeb News) - Becton Dickinson expects to complete the sale of its Clontech division in the second or third quarter, the company said.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.